Cerevance (Group)

https://www.cerevance.com

LinkedIn: https://www.linkedin.com/company/cerevance

Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), that demonstrated significant and clinically meaningful efficacy in a 135-patient Phase 2 study in patients with Parkinson’s disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify highly selectively expressed, novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering with over 25 brain banks and evaluating an expanding collection of more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. *

	Start	2015-10-01 established
	Industry	CNS drug (neurological drug)
	Person	Margus, Brad (Cerevance 201510– CEO + Founder before Perlegen 200501 CEO)

	Region	Boston, MA
	Country	United States (USA)
	Street	One Marina Park Drive Suite 1410
	City	02210 Boston, MA
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Cerevance. (2/23/23). "Press Release: Cerevance Expands Series B Financing with Additional $51 Million". Boston, MA.

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Cerevance (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)